Source comparison
MOTS-C Support Weight Loss Without GLP-1: Comparison
Primary Mechanism AMPK activation → mitochondrial fat oxidation, increased glucose disposal in muscle GLP-1 receptor agonism → appetite suppression, delayed gastric emptying, enhanced insulin secretion Dual pathway: appetite reduction + cellular energy expendi
This comparison does not assign a generated winner or score.
- Primary Mechanism
- AMPK activation → mitochondrial fat oxidation, increased glucose disposal in muscle
- GLP-1 receptor agonism → appetite suppression, delayed gastric emptying, enhanced insulin secretion
- Dual pathway: appetite reduction + cellular energy expenditure
- MOTS-c addresses expenditure; GLP-1 addresses intake. Mechanisms are complementary
- Expected Weight Loss (12 weeks)
- 2–4% body weight, primarily fat mass with lean mass preservation
- 8–15% body weight (dose-dependent), majority from caloric deficit
- Potentially 10–18% (hypothetical. No clinical trials exist)
- GLP-1 produces greater absolute weight loss; MOTS-c may offer superior body composition outcomes
- Appetite Effect
- No direct appetite suppression
- Significant appetite reduction, early satiety, reduced food cravings
- Appetite suppression from GLP-1 component only
- MOTS-c does not reduce hunger. Caloric deficit must be managed behaviourally if used alone
- Insulin Sensitivity
- Improved via AMPK-mediated glucose uptake in muscle, reduced hepatic glucose output
- Improved indirectly through weight loss and beta-cell support
- Additive improvement through distinct pathways
- MOTS-c may benefit insulin resistance independently of weight loss. A key distinction
- Discontinuation Effect
- Metabolic improvements may persist longer due to mitochondrial adaptation
- Rapid weight regain in most patients (two-thirds of lost weight within 12 months)
- Unknown. Combination discontinuation effects unstudied
- MOTS-c's mitochondrial effects may confer more durable metabolic changes than GLP-1's transient appetite suppression